NeoImmuneTech, Inc. (KOSDAQ:950220)

NeoImmuneTech Statistics

Total Valuation

NeoImmuneTech has a market cap or net worth of KRW 46.27 billion. The enterprise value is -4.06 billion.

Market Cap	46.27B
Enterprise Value	-4.06B

Important Dates

The next estimated earnings date is Thursday, May 14, 2026.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

NeoImmuneTech has 98.87 million shares outstanding. The number of shares has increased by 19.34% in one year.

Current Share Class	n/a
Shares Outstanding	98.87M
Shares Change (YoY)	+19.34%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.96%
Owned by Institutions (%)	n/a
Float	88.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	487.96
PB Ratio	0.78
P/TBV Ratio	1.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.13
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.16

Financial Position

The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.18.

Current Ratio	3.08
Quick Ratio	2.94
Debt / Equity	0.18
Debt / EBITDA	n/a
Debt / FCF	-0.42
Interest Coverage	-10.45

Financial Efficiency

Return on equity (ROE) is -63.04% and return on invested capital (ROIC) is -25.93%.

Return on Equity (ROE)	-63.04%
Return on Assets (ROA)	-21.48%
Return on Invested Capital (ROIC)	-25.93%
Return on Capital Employed (ROCE)	-41.29%
Weighted Average Cost of Capital (WACC)	8.51%
Revenue Per Employee	1.82M
Profits Per Employee	-611.46M
Employee Count	52
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-11.37M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -58.73% in the last 52 weeks. The beta is 0.37, so NeoImmuneTech's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	-58.73%
50-Day Moving Average	526.32
200-Day Moving Average	741.88
Relative Strength Index (RSI)	36.97
Average Volume (20 Days)	1,339,500

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NeoImmuneTech had revenue of KRW 94.82 million and -31.80 billion in losses. Loss per share was -270.20.

Revenue	94.82M
Gross Profit	94.82M
Operating Income	-25.34B
Pretax Income	-31.81B
Net Income	-31.80B
EBITDA	-22.84B
EBIT	-25.34B
Loss Per Share	-270.20

Balance Sheet

The company has 60.82 billion in cash and 10.49 billion in debt, with a net cash position of 50.33 billion or 509.07 per share.

Cash & Cash Equivalents	60.82B
Total Debt	10.49B
Net Cash	50.33B
Net Cash Per Share	509.07
Equity (Book Value)	59.21B
Book Value Per Share	413.52
Working Capital	43.12B

Cash Flow

In the last 12 months, operating cash flow was -25.05 billion and capital expenditures -79.64 million, giving a free cash flow of -25.13 billion.

Operating Cash Flow	-25.05B
Capital Expenditures	-79.64M
Depreciation & Amortization	2.50B
Net Borrowing	-792.78M
Free Cash Flow	-25.13B
FCF Per Share	-254.20

Margins

Gross Margin	100.00%
Operating Margin	-26,721.84%
Pretax Margin	-33,543.38%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NeoImmuneTech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.34%
Shareholder Yield	-19.34%
Earnings Yield	-68.72%
FCF Yield	-54.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NeoImmuneTech has an Altman Z-Score of -3.73 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.73
Piotroski F-Score	2